CytoMed Therapeutics (GDTC) Receivables (2021 - 2025)
CytoMed Therapeutics (GDTC) posted Receivables of $456111.4 for Q4 2025, down 56.4% sequentially from $1.0 million in Q2 2025, and down 60.35% YoY from $1.2 million in Q4 2024.
CytoMed Therapeutics (GDTC) Receivables (2021 - 2025) Analysis & Trends
CytoMed Therapeutics has reported Receivables for 5 years, with the latest figure at $456111.4 in Q4 2025.
- Quarterly Receivables fell 60.35% year-over-year to $456111.4 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $456111.4 (down 60.35% YoY) and the FY2025 annual result came in at $1.6 million, up 37.28% from the prior year.
- Receivables retreated to $456111.4 in Q4 2025 per GDTC's latest filing, from $1.0 million in the prior quarter.
- Over five years, Receivables peaked at $1.2 million in Q2 2024 and troughed at $105409.6 in Q4 2022.
- A 5-year average of $833156.1 and a median of $1.0 million in 2023 frame the typical range for Receivables.
- The sharpest annual moves came in 2022 and 2023: Receivables plunged 81.88% in 2022, then surged 856.13% in 2023.
- Over 5 years, Receivables stood at $581771.7 in 2021, then slumped by 81.88% to $105409.6 in 2022, then soared by 856.13% to $1.0 million in 2023, then grew by 14.15% to $1.2 million in 2024, then sank by 60.35% to $456111.4 in 2025.
- According to Business Quant data, Receivables over the past three periods registered $456111.4, $1.0 million, and $1.2 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.75 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.09 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 59.14 Bn | 54.00 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | - |
| 10 | CytoMed Therapeutics | 9.97 Mn | 8.35 Mn | - | 1.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 456,111.37 |
| Jun 30, 2025 | 1.05 Mn |
| Dec 31, 2024 | 1.15 Mn |
| Jun 30, 2024 | 1.25 Mn |
| Dec 31, 2023 | 1.01 Mn |
| Jun 30, 2023 | 1.07 Mn |
| Dec 31, 2022 | 105,409.57 |
| Dec 31, 2021 | 581,771.65 |